CTC
BHVN

Central Trust Company’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Central Trust Company’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-106
Closed -$15K – 1453
2022
Q2 		$15K Hold
106
– – ﹤0.01% 986
2022
Q1 		$13K Buy
106
+6
+6% +$748 ﹤0.01% 1051
2021
Q4 		$14K Hold
100
– – ﹤0.01% 1016
2021
Q3 		$14K Hold
100
– – ﹤0.01% 988
2021
Q2 		$10K Buy
+100
New +$8.12K ﹤0.01% 1030

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Central Trust Company's BHVN Position: Q3 2022 in Review

Central Trust Company sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 106 shares — an estimated $15K sold.

Central Trust Company first reported a position in BHVN in Q2 2021 and held it in 5 quarters. The position peaked at $15K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Central Trust Company reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Central Trust Company sold 106 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $15K.
  • Central Trust Company first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and held it in 5 quarters.
  • Central Trust Company's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $15K in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Central Trust Company's 13F filing for Q3 2022, filed 3 Nov 2022.